Oncternal Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Oncternal Therapeutics

10/08/2023 22:03

* Oncternal Therapeutics Inc  ONCT.OQ  reported a quarterly
adjusted loss of 15 cents​​ per share for the quarter ended in
June. The mean expectation of six analysts for the quarter was
for a loss of 16 cents per share.
    * Revenue fell 44.5% to $106.00 thousand from a year ago;
analysts
expected $205.00 thousand. 
    * Oncternal Therapeutics Inc's reported EPS for the quarter
was a
loss of 15 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Oncternal Therapeutics Inc shares had risen by 5.3% this
quarter and lost 63.7% so far this year.
    * The company reported a quarterly loss of $8.97 million.
    * Wall Street's median 12-month price target for Oncternal
Therapeutics Inc is $1.90 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 5
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 10 at 09:02 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.16          -0.15          Beat
 Mar. 31 2023      -0.20          -0.20          Met
 Dec. 31 2022      -0.21          -0.20          Beat
 Sep. 30 2022      -0.24          -0.21          Beat